



## Chalcones, coumarins, and flavanones from the exudate of *Angelica keiskei* and their chemopreventive effects

Toshihiro Akihisa<sup>a,\*</sup>, Harukuni Tokuda<sup>b</sup>, Motohiko Ukiya<sup>a</sup>, Masao Iizuka<sup>a</sup>, Stefan Schneider<sup>a</sup>, Kazuya Ogasawara<sup>c</sup>, Teruo Mukainaka<sup>b</sup>, Kenji Iwatsuki<sup>d</sup>, Takashi Suzuki<sup>e</sup>, Hoyoku Nishino<sup>b</sup>

<sup>a</sup>College of Science and Technology, Nihon University, 1-8 Kanda Surugadai, Chiyoda-ku, Tokyo 101-8308, Japan

<sup>b</sup>Department of Biochemistry, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-0841, Japan

<sup>c</sup>Japan Bio Science Laboratory Co., Ltd, 2022 Shioya, Aki-machi, Higashikunisaki-gun, Oita 873-0212, Japan

<sup>d</sup>K-Laboratories for Intelligent Medical Remote Services, 2266-22 Anagahora, Shimoshidami, Moriyama-ku, Nagoya 463-0003, Japan

<sup>e</sup>College of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan

Received 14 May 2003; received in revised form 25 June 2003; accepted 30 June 2003

### Abstract

From an ethyl acetate-soluble fraction of the exudate obtained from the stems of *Angelica keiskei* (Umbelliferae), 17 compounds, viz. five chalcones (**1–5**), seven coumarins (**6–12**), three flavanones (**13–15**), one diacetylene (**16**), and one 5-alkylresorcinol (**17**), were isolated. These compounds were evaluated with respect to their inhibitory effects on the induction of Epstein-Barr virus early antigen (EBV-EA) by 12-*O*-tetradecanoylphorbol-13-acetate (TPA) in Raji cells, which is known to be a primary screening test for antitumor-promoters. With the exception of three compounds (**10**, **16**, and **17**), all other compounds tested showed potent inhibitory effects on EBV-EA induction (92–100% inhibition at  $1 \times 10^3$  mol ratio/TPA). In addition, upon evaluation of these compounds for the inhibitory effects against activation of ( $\pm$ )-(*E*)-methyl-2-[(*E*)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor, as a primary screening test for antitumor-initiators, two chalcones (**2** and **3**) and six coumarins (**6–11**) exhibited potent inhibitory effects.

© 2003 Elsevier Ireland Ltd. All rights reserved.

**Keywords:** *Angelica keiskei*; Umbelliferae; Chalcones; Coumarins; Flavanones; Chemopreventive effects; Antitumor-promoter; Epstein-Barr virus; Antitumor-initiator

### 1. Introduction

*Angelica keiskei* KOIDZUMI (Japanese name ‘Ashitaba’, Umbelliferae) is a hardy perennial herb, growing mainly along the Pacific coast of Japan,

that is traditionally used as a diuretic, laxative, analeptic and lactagogue [1]. The fresh leaves of this plant and its dry powder are used for food. Various chalcones [1–6], represented by xanthoangelol (**1**) and 4-hydroxyderricin (**4**), and coumarins [1,3,6] have so far been isolated and characterized from the plant. The two chalcones **1** and **4** have been proved to have antitumor-promoting activity in mouse

\* Corresponding author. Fax: +81-3-3293-7572.

E-mail address: [akihisa@chem.cst.nihon-u.ac.jp](mailto:akihisa@chem.cst.nihon-u.ac.jp) (T. Akihisa).

skin carcinogenesis induced by 7,12-dimethylbenz[*a*]anthracene (DMBA) plus 12-*O*-tetradecanoylphorbol-13-acetate (TPA) [6]. In this paper, we report the isolation and identification of 17 compounds from an ethyl acetate (EtOAc)-soluble fraction of the exudate of *Ashitaba* stems and inhibitory effects on the induction of Epstein-Barr virus early antigen (EBV-EA) by TPA and on activation of ( $\pm$ )-(*E*)-methyl-2-[(*E*)-hydroxy-imino]-5-nitro-6-methoxy-3-hexamide (NOR 1), a nitric oxide (NO) donor, of 17 compounds, **1**–**17**, evaluated in a preliminary screen for their potential cancer chemopreventive activities.

## 2. Materials and methods

### 2.1. Extraction and isolation

Lyophilized and powdered exudate (4.93 g) obtained from the stems of *Angelica keiskei* (Hachijo-type) [1], cultivated in the farm at Lombok island (Indonesia) and harvested in 2000, was partitioned with *n*-hexane-methanol (MeOH)–H<sub>2</sub>O (95:95:10, v/v/v) to give a MeOH–H<sub>2</sub>O soluble fraction (4.55 g) which was further partitioned between ethyl acetate (EtOAc) and H<sub>2</sub>O (1:1, v/v). The EtOAc soluble fraction (0.93 g) was subjected to medium-pressure liquid chromatography (MPLC) on an ODS column (50 cm  $\times$  25 mm i.d.; eluting solvent, MeOH; flow rate, 3.0 ml/min) which yielded fractions A [357 mg; retention time ( $t_R$ ) 29.6 min], B (439 mg;  $t_R$  31.6 min), and C (74 mg,  $t_R$  40.4 min). Upon preparative HPLC on an ODS column (25 cm  $\times$  10 mm i.d.; eluting solvent, MeOH–H<sub>2</sub>O–acetic acid, 65:35:1, v/v/v; flow rate, 2.0 ml/min), fraction A gave xanthoangelol (**1**) [4] (5.4 mg), isobavachalcone (**3**) [7] (8.6 mg), xanthoangelol H (**5**) [5] (1.4 mg), laserpitin (**6**) [8] (31.2 mg), isolaserpitin (**7**) [8] (15.6 mg), 3'-senecioidyl khellactone (**8**) [8] (1.9 mg), 4'-senecioidyl khellactone (**9**) [8] (3.7 mg), selinidin (**10**) [8] (6.8 mg), pteryxin (**11**) [9] (2.6 mg), (3'*R*)-3'-hydroxycolumbianidin (**12**) [10] (2.5 mg), mundulea flavanone A (**13**) [11] (1.7 mg), prostratol F (**14**) [7] (7.4 mg), and falcarindiol (**16**) [12] (14.0 mg) (see Fig. 1 for the structure); fraction B gave **1** (121.7 mg), **3** (1.3 mg), 4-hydroxyderricin (**4**) [4] (70.8 mg), **6** (3.8 mg), **7** (10.7 mg), **10** (15.1 mg),

**13** (4.0 mg), **14** (1.0 mg), and **15** (1.7 mg); and fraction C yielded xanthoangelol F (**2**) [5] (35.0 mg), **4** (2.0 mg), 4'-*O*-geranylningenin (**15**) [13] (3.2 mg), and 5-*n*-pentadecylresorcinol (**17**) [14] (2.6 mg). Identification of all of the above compounds was performed by MS and <sup>1</sup>H NMR comparison with the literature.

### 2.2. Chemicals

The cell culture reagents and *n*-butyric acid from Nacalai Tesque, Inc. (Kyoto, Japan), TPA,  $\beta$ -carotene, and glyzyrrhizin from Sigma Co., NOR 1 and carboxy-PTIO [2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide potassium salt] from Dojindo Laboratories (Kumamoto, Japan), were purchased.

### 2.3. In vitro EBV-EA induction tests

The EBV genome-carrying lymphoblastoid cells, Raji cells, derived from Burkitt's lymphoma, were cultured in RPMI-1640 medium. The Raji cells were incubated for 48 h at 37 °C in a medium containing *n*-butyric acid (4 mM), TPA (32 pM), and various amounts of test compounds. Smears were made from the cell suspension, and the EBV-EA-inducing cells were stained by means of an indirect immunofluorescence technique. The details of the in vitro assay on EBV-EA induction have been reported previously [15].

### 2.4. In vitro NOR 1 inhibition tests [16]

Chang liver cells (normal human hepato cells;  $5 \times 10^5$ /ml), derived from human liver in MEM Eagle medium, were cultured three days before treatment. NOR 1 was added into culture dish and incubated for 1 h under CO<sub>2</sub> incubator as control. For screening assay, test samples to culture dish were added before 1 min of NOR 1 treatment. Transformed cells were observed under light-microscopy ( $\times 100$ ). All observed cells count for more than 250. The inhibitory ratio was then calculated:




Fig. 1. Structures of compounds isolated from the exudate of *Angelica keiskei* stems.

#### Inhibitory ratio (IR)

$$= \frac{\text{transformed cell\% (NOR 1 alone)}}{\text{transformed cell\% (NOR 1 + test sample)}}$$

### 3. Results and discussion

In this study, we were able to isolate five chalcones (1–5), seven coumarins (6–12), three flavanones (13–15), one diacetylene (16), and one 5-alkylresorcinol (17) from an EtOAc-soluble fraction of the exudate obtained from *Ashitaba* stems. The inhibitory effects on the induction of EBV-EA induced by TPA were examined as a preliminary evaluation of the potent antitumor-promoting activities for these

compounds. The inhibitory effects (Table 1) were compared with those of reference compound,  $\beta$ -carotene, a vitamin A precursor that has been studied intensively in cancer chemoprevention using animal models [17]. With the exception of three compounds (10, 16, and 17), all other compounds tested exhibited potent inhibitory effects (92–100% inhibition at  $1 \times 10^3$  mol ratio, and 51–84% inhibition at  $5 \times 10^2$  mol ratio), and among which two chalcones, 3 and 4, and three flavanones, 13–15, exhibited remarkably high inhibitory effects (100% inhibition at  $1 \times 10^3$  mol ratio), on EBV-EA induction by TPA with preservation of the high viability (60–70%) of the Raji cells. The inhibitory effects of these compounds were equivalent to or more potent than  $\beta$ -carotene. Since two chalcones, 1 and 4, have

Table 1

Inhibitory effects on the induction of Epstein-Barr Virus Early Antigen and Inhibitory Ratio (IR) on NOR 1 action of compounds **1–17** isolated from *Angelica keiskei* and reference compounds

Compound	Percentage of EBV-EA induction <sup>a</sup>					IR of NOR 1 activation <sup>b</sup>	
	Concentration (mol ratio/TPA)						
	1000		500	100	10		
<i>Chalcone</i>							
<b>1</b>	Xanthoangelol	1.8	(60)	19.7	65.0	90.0	1.9
<b>2</b>	Xanthoangelol F	2.1	(60)	21.6	68.3	91.0	2.4
<b>3</b>	Isobavachalcone	0	(60)	16.3	63.0	88.4	2.0
<b>4</b>	4-Hydroxyderricin	0	(60)	17.3	64.1	93.2	1.8
<b>5</b>	Xanthoangelol H	5.3	(60)	32.4	71.5	95.0	1.5
<i>Coumarin</i>							
<b>6</b>	Lasepitin	0.3	(60)	48.9	78.3	100	2.0
<b>7</b>	Isolaserpitin	8.5	(60)	46.7	76.2	98.4	2.1
<b>8</b>	3'-Senecioid khellactone	7.1	(60)	45.3	74.4	96.3	2.1
<b>9</b>	4'-Senecioid khellactone	7.1	(60)	42.3	72.5	94.0	2.1
<b>10</b>	Selinidin	19.5	(60)	47.7	77.2	100	2.0
<b>11</b>	Pteryxin	4.3	(60)	41.0	72.4	93.2	2.2
<b>12</b>	(3'R)-3'-Hydroxycolumbianadin	3.5	(60)	40.3	71.7	93.0	1.5
<i>Flavanone</i>							
<b>13</b>	Munduleaflavanone A	0	(70)	25.2	69.3	90.3	1.7
<b>14</b>	Prostratol F	0	(70)	28.6	70.6	92.1	1.9
<b>15</b>	4'-O-Geranylaringenin	0	(60)	20.3	73.1	93.2	1.9
<i>Others</i>							
<b>16</b>	Falcarindiol	23.1	(60)	56.3	85.5	100	1.5
<b>17</b>	5- <i>n</i> -Pentadecylresorcinol	12.4	(60)	45.9	74.1	100	1.8
<i>Reference compound</i>							
	β-Carotene	8.6	(70)	34.2	82.1	100	
	Glyzyrrhizin	26.4	(>80)	63.3	83.3	100	2.2
	Carboxy-PTIO						8.0

<sup>a</sup> Values represent percentages relative to the positive control value. TPA (3 pmol, 20 ng) = 100%. Values in parentheses are viability percentages of Raji cells.

<sup>b</sup> Determined at the concentration of 350 nmol. Inhibitory ratio of NOR 1 (positive control; 350 nmol) was taken as 1.0.

already been proved to have antitumor-promoting activity in mouse skin carcinogenesis using DMBA as an initiator and TPA as a promoter [6], and since the inhibitory effects against EBV-EA induction have been demonstrated to closely parallel those against tumor promotion in vivo [15], the three other chalcones (**2**, **3**, **5**), six coumarins (**6–9**, **11**, **12**), and three flavanones (**13–15**), also are suggested to be valuable antitumor-promoters. Details of the specificity of EBV-EA induction test were described previously [18].

Using in vitro screening models for nitric oxide (NO) scavenging [16], 17 compounds, **1–17**, from *Ashitaba* exudate were evaluated for their

scavenging activity against NO generation by NOR 1 in cultured cell system. Table 1 showed the inhibitory ratios (IR) of the compounds and two reference compounds: a natural compound, glycyrrhizin, and a synthetic NO scavenger, carboxy-PTIO, on NOR 1 action. Among the compounds tested, two chalcones, **2** and **3**, and six coumarins, **6–11**, exhibited potent inhibitory effects (IR = 2.0–2.4) which were almost equivalent to that of glycyrrhizin (IR = 2.2).

From the results of in vitro EBV-EA induction and in vitro NOR 1 inhibition tests, it might be suggested that chalcones, coumarins, and flavanones from the exudate of *Ashitaba* stems to be useful as

chemopreventive agents in chemical carcinogenesis, and the exudate of *Ashitaba* stems are valuable food ingredient by containing these compounds abundantly.

### Acknowledgements

This study was supported in part by Grants-in-Aid from the Ministry of Education, Science and Culture, and the Ministry of Health and Welfare of Japan, and this study was also supported in part by a grant from the National Cancer Institute (CA 177625), USA.

### References

- [1] K. Baba, M. Taniguchi, K. Nakata, Studies on *Angelica keiskei* ashitaba, *Foods Food Ingredients J. Jpn.* 178 (1998) 52–60.
- [2] M. Kozawa, N. Morita, K. Baba, H. Hata, Chemical components of the roots of *Angelica keiskei* KOIDZUMI. II. The structure of chalcone derivatives, *Yakugaku Zasshi* 98 (1978) 210–214.
- [3] K. Baba, T. Kido, Y. Yoneda, M. Taniguchi, M. Kozawa, Chemical components of *Angelica keiskei* KOIDZUMI (V) Components of the fruits, and comparison of coumarins and chalcones in the fruits, roots and the leaves, *Syoyakugaku Zasshi* 44 (1990) 235–239.
- [4] K. Baba, K. Nakata, M. Taniguchi, T. Kido, M. Kozawa, Chalcones from *Angelica keiskei*, *Phytochemistry* 29 (1990) 3907–3910.
- [5] K. Nakata, M. Taniguchi, K. Baba, Three chalcones from *Angelica keiskei*, *Nat. Med.* 53 (1999) 329–332.
- [6] T. Okuyama, M. Takata, J. Takayasu, T. Hasegawa, H. Tokuda, A. Nishino, H. Nishino, A. Iwashima, Anti-tumor-promotion by principles obtained from *Angelica keiskei*, *Planta Med.* 57 (1991) 242–246.
- [7] M. Iinuma, M. Ohyama, T. Tanaka, Two flavanones from roots of *Sophora leachiana*, *Phytochemistry* 38 (1995) 539–543.
- [8] T.M. Swager, J.H. Cardellina II, Coumarins from *Musineon divaricatum*, *Phytochemistry* 24 (1985) 805–813.
- [9] I.S. Chen, C.T. Chang, W.S. Sheen, C.M. Teng, I.L. Tsai, C.Y. Duh, F.N. Ko, Coumarins and antiplatelet aggregation constituents from Formosan *Peucedanum japonicum*, *Phytochemistry* 41 (1996) 525–530.
- [10] K. Baba, T. Hamasaki, Y. Tabata, M. Kozawa, Y. Honda, M. Tabata, Chemical studies on Chinese crude drug 'She Chuang Zi', *Syoyakugaku Zasshi* 39 (1985) 282–290.
- [11] E. Venkata Rao, P. Sridhar, R. Prasad, Two prenylated flavanones from *Mundulea suberosa*, *Phytochemistry* 46 (1997) 1221–1274.
- [12] A. Satoh, Y. Narita, N. Endo, H. Nishimura, Potent allelochemical falcilindiol from *Glehnia littoralis* F. Schm, *Biosci. Biotech. Biochem.* 60 (1996) 152–153.
- [13] M. Ahsan, J.A. Armstrong, S. Gibbons, A.I. Gray, P.G. Waterman, Novel *O*-prenylated flavonoids from two varieties of *Boronia coerulescens*, *Phytochemistry* 37 (1994) 259–266.
- [14] D.D. Ridley, E. Ritchie, W.C. Taylor, Chemical studies of the Proteaceae II. Some further constituents of *Grevillea robusta* A. Cunn.; Experiments on the synthesis of 5-*n*-tridecylresorcinol (grevillol) and related substances, *Aust. J. Chem.* 21 (1968) 2079–2988.
- [15] Y. Takaishi, K. Ujita, H. Tokuda, H. Nishino, A. Iwashima, T. Fujita, Inhibitory effects of dihydroagarofuran sesquiterpenes on Epstein-Barr virus activation, *Cancer Lett.* 65 (1992) 19–26.
- [16] H. Tokuda, M. Kuchide, M. Okuda, T. Mukainaka, Y. Nobukuni, J. Takayasu, H. Nishino, Chemopreventive activity of antioxidants on nitric oxide donors induced mouse skin carcinogenesis, *Proc. Am. Assoc. Cancer Res.* #5674 (2002) 1145.
- [17] A. Murakami, H. Ohigashi, K. Koshimizu, Anti-tumor promotion with food phytochemicals: A strategy for cancer chemoprevention, *Biosci. Biotech. Biochem.* 60 (1996) 1–8.
- [18] Y. Ito, H. Tokuda, H. Ohigashi, K. Koshimizu, Distribution and characterization of environmental promoter substances as assay by synergistic Epstein-Barr virus-activating system, in: H. Fujiki, et al. (Eds.), *Cellular Interactions by Environmental Tumor Promoters*, VNU Science Press, Utrecht, 1984, pp. 125–137.